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ABSTRACT
One of the major obstacles to the pharmaceutical
success of oligonucleotide therapeutics (ONTs) is
efficient delivery from the point of injection to the
intracellular setting where functional gene silencing
occurs. In particular, a significant fraction of internal-
ized ONTs are nonproductively sequestered in endo-
lysosomal compartments. Here, we describe a two-
step, robust assay for high-throughput de novo de-
tection of small bioactive molecules that enhance
cellular uptake, endosomal escape, and efficacy of
ONTs. Using this assay, we screened the LOPAC
(Sigma–Aldrich) Library of Pharmacologically Ac-
tive Compounds and discovered that Guanabenz ac-
etate (WytensinTM), an FDA-approved drug formerly
used as an antihypertensive agent, is capable of
markedly increasing the cellular internalization and
target mRNA silencing of hydrophobically modified
siRNAs (hsiRNAs), yielding a ∼100-fold decrease in
hsiRNA IC50 (from 132 nM to 2.4 nM). This is one
of the first descriptions of a high-throughput small-
molecule screen to identify novel chemistries that
specifically enhance siRNA intracellular efficacy, and
can be applied toward expansion of the chemical di-
versity of ONTs.
INTRODUCTION
Synthetic oligonucleotides, including antisense (ASOs),
splice-switching (SSOs), N-acetylgalatosamine (GalNAc)-
siRNAs, miRNA modulators, LNPs and hsiRNA, are
abundantly used to manipulate gene expression in biomed-
ical research and hold great promise for becoming a break-
through treatment in a variety of human genetic diseases
(1,2). A wide range of delivery issues limits the clinical util-
ity of these classes of compounds. For instance, a relatively
small fraction of intracellular ONTs are biologically ac-
tive, with the vast majority being trapped unproductively in
‘oligonucleotide sinks’ (3–6). This defines the need for high
doses, which in turn may lead to toxicity and off-target ef-
fects. Nonproductive accumulation in subcellular compart-
ments is generally considered the rate-limiting step for pro-
ductive mRNA silencing (7). With therapeutic IC50 values
in the nano- to picomolar range, millions of copies of ONTs
are delivered per cell while less than 500RNA-loadedRNA-
induced silencing complexes (RISC) are required for activ-
ity (8). Therefore, solving the intracellular bio-distribution
challenge is a fundamental step in optimizing RNA thera-
peutics for clinical use.
A decade of research has focused on designing modifi-
cations, conjugates, and carriers for improving ONT deliv-
ery, yet no ideal configuration (with the exception of N-
acetylgalatosamine (GalNAc)-conjugated siRNA for deliv-
ery to hepatocytes) has emerged (9). Here, we decided to ex-
plore whether co-delivery of small molecules could improve
the uptake and activity of cholesterol-modified siRNA-
antisense hybrids, termed hsiRNA (10). Large delivery con-
structs, including dendrimers (11), cell-penetrating peptides
(12,13), polymers such as dynamic polyconjugates (14,15),
and nanoparticles (7) have been used previously as part
of siRNA formulations, but the use of small molecule
drugs as modulators of ONT efficacy is relatively unex-
plored and limited to several recent studies. First, Gooding
et al. have reported the synthesis of small molecule carriers
(SMoC) of siRNA, which form non-covalent electrostatic
interactions with unmodified siRNA to enhance plasma
membrane translocation (16,17). Second, Juliano’s group
demonstrated that the small molecule Retro-1, which is in-
volved in retrograde transport of bacterial toxins, apprecia-
bly improved the activity of nuclear-localized ASOs follow-
ing simultaneous transfection. This year, a publication from
the same group reported an extensive screen identifying
compounds that enhance antisense ONT efficacy (18,19).
Collectively, these studies highlight the potential for small
molecules to act as powerful gene silencing effectors. Here,
we developed an unbiased, systematic protocol to explore
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the ease and feasibility of using small molecule screening to
identify novel modulators of oligonucleotide efficacy.
MATERIALS AND METHODS
Oligonucleotides and small molecule compounds
All oligonucleotide sequences and modification patterns
synthesized in-house are summarized in Supplementary Ta-
ble S1. Accell siRNA (Thermo Fisher) targeting HTT was
purchased and used without further purification. Clonidine
(Sigma–Aldrich), Retro-1 (Sigma–Aldrich) and Salubrinal
(Sigma–Aldrich) were dissolved in DMSO and stored as 10
mM stock solutions at −20◦C. Unless otherwise specified,
all oligonucleotides and small molecules were diluted inOp-
tiMEM (Gibco) prior to administration in vitro.
Cell culture
HeLa cells were maintained in DMEM (Invitrogen) sup-
plemented with 100U/ml penicillin and streptomycin (In-
vitrogen) and 10% fetal bovine serum (Gibco) at 37◦C
and 5% CO2. Human primary hepatocytes (Gibco) were
thawed and plated in Williams E Medium (Gibco) supple-
mented with 5% fetal bovine serum, 1 M dexamethasone
in DMSO, 100 U/ml penicillin and streptomycin, 4 g/ml
human recombinant insulin, 2 mM GlutaMAXTM, and 15
mM HEPES pH 7.4 at 37◦C and 5% CO2. Plated hepa-
tocytes were allowed to recover for 6 h and subsequently
maintained in Williams E Medium (Gibco) supplemented
with 0.1 M dexamethasone in DMSO, 50 U/ml penicillin
and streptomycin, 6.25 g/ml human recombinant insulin,
6.25 g/ml human transferrin, 6.25 g/ml selenous acid,
6.25g/ml bovine serum albumin, 6.25g/ml linoleic acid,
2 mM GlutaMAXTM,15 mM HEPES pH 7.4 and 5 mM
CaCl2 at 37◦C and 5% CO2.
LOPAC1280 small molecule primary screen
HeLa cells were purchased from the University of Mas-
sachusetts (Worcester, MA, USA) tissue culture facility and
verified to be Mycoplasma negative. A hsiRNA-targeting
sequence (from theMAP4K4 gene)(10) was cloned into the
3′UTR of Renilla luciferase within a standard psiCHECK2
vector. This plasmid also contains a Firefly luciferase re-
porter gene used for transfection normalization and cell
variability. psiCHECK2 plasmid amplification was per-
formed using the EndoFree Plasmid Maxi kit (Qiagen)
following the manufacturer’s recommended instructions.
psiCHECK2 plasmid concentration was measured by Nan-
odrop and diluted to a final concentration of 1 g/l.
LOPAC1280 was purchased directly from Sigma-Aldrich
in a 96-well plate format (16 plates total). Each small
molecule was provided in a stock solution of 10 mM (250
l) inDMSO. Each plate was diluted to 5mM for screening.
For the primary screen, HeLa cells were seeded in T-175
flasks at 3 × 106 cells/ml in 10 ml and cultured for 20 h un-
der standard conditions. The cells were then sub-cultured
in 6% DMEM without antibiotics. After 6 h, psiCHECK2
plasmid was transfected using Lipofectamine2000 at a 1:2.5
ratio. After 7 h transfection, cell media was replaced with
fresh DMEM and cells were incubated under standard
conditions overnight. The following day, 50 l of 0.02
M MAP4K4-targeting hsiRNA dissolved in OptiMEM
(Gibco) was added to 16 plates (Costar #3610, cell culture
treated, bottom clear, white) in columns 2–11 and Wells
E1-H1. This final concentration (10 nM) was selected as it
typically induces minimal silencing (5–10%) after passive
uptake over 24 h. In each plate, 50 l of 1 M hsiRNA
(MAP4K4) was added in Wells A1-D1 as a positive con-
trol and 50 l of 1 M hsiRNA (NTC) was added in Wells
A12-D12 as a negative control. Wells E12-H12 contained
no hsiRNA (only 50 l Opti-MEMminimal medium). Fol-
lowing addition of hsiRNA to each plate, 1 ul of 5 mM
LOPAC compounds was added by a liquid handler (Tecan,
TeMo).
psiCHECK2 transfected cells were collected by
trypsinization and resuspended in DMEM containing
6% FBS without antibiotics. 15 000 cells/50 ul were added
to each preparedwell and incubated for 72 h under standard
conditions. After 72 h, all 16 plates were assayed with the
Dual-Glo kit (Promega) following the manufacturer’s rec-
ommended protocol. Briefly, 50 l of Dual-Glo luciferase
substrate was added to each well. Firefly luminescence
signal (fLUC) was read after 15 min using an EnVision
plate reader (Perkin Elmer) with a 0.1 s integration time.
Then, 50 l of Stop-Glo substrate was added. Following a
second 15 min incubation period, Renilla luciferase signal
(rLUC) was recorded as described previously. The ratio
of rLUC/fLUC was used for screening data analysis. The
average calculated screening Z′ factor (Eq. 1) was 0.53,
CV% = 10.7% and S/B = 13.9, representing a robotic
performance.
Z′ = 1 − 3 ∗ (σ− + σ+)
μ+ − μ− (1)
Calculation of Z′ factor. σ+ and σ - represent standard de-
viation of positive and negative control. μ+ and μ- repre-
sent average of positive and negative controls, respectively.
65 small molecules that induced>50% enhancement in nor-
malized luciferase knockdown were scored (5% hit rate).
These primary hits were divided into three categories: (1)
significant knockdown (15 hits), (2) knockdown that may
be due to firefly signal increase (24 hits) and (3) much higher
firefly signal (26 hits). We selected all hits from category 1,
seven hits from category 2, and two hits from category 3 (24
total) for the secondary screen.
LOPAC1280 small molecule secondary screen
The QuantiGene 2.0 bDNA assay (Affymetrix, QS0011)
was used to perform a secondary validation screen on the
primary hits. 50 l of 0.1 MMAP4K4-targeting hsiRNA
was added to a 96 well plate with 1 M NTC and 1 M
MAP4K4-targeting hsiRNA as negative and positive con-
trols, respectively. Then, 1 L of 24 hits was added at three
different concentrations (50 M, 20 M, or 5 M). HeLa
cells, previously resuspended in 6% FBS DMEM media
without antibiotics, were added into eachwell with a density
of 10 000 cells/50 l per well. Mixture was incubated under
standard conditions for 72 h. After 72 h, cells were lysed and
processed according to the manufacturer’s recommended
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protocol. Briefly, cells were lysed in 250 l diluted lysis mix-
ture (1:2 lysis mixture:H2O) with 0.167 ug/ul proteinase K
(Affymetrix, QS0103) for 30 min at 55◦C. Cell lysates were
mixed thoroughly and 40 l (∼8,000 cells) of lysate were
added to a bDNA capture plate along with 40 l additional
diluted lysis mixture without proteinase K. Probe sets were
diluted as specified in Affymetrix protocol and 20 l of ei-
ther human HTT or PPIB probes (Affymetrix: SA-50339,
SA-10003) were added to each well of capture plate to a
final volume of 100 l. Luminescence was detected on ei-
ther a Veritas Luminometer or a Tecan M 1000. Follow-
ing analysis ofMAP4K4 mRNA expression normalized to
PPIB housekeeping mRNA expression, six small molecule
hits out of 24 were confirmed to have constitutive activity.
LOPAC1280 small molecule tertiary screen
Six secondary hits (0.5%hit rate) were analyzed as described
above for the secondary screen using a PPIB-targeting
hsiRNA to confirm that activity is not RNA sequence de-
pendent. Based on reproducibility and toxicity profile (Sup-
plementary Figures S6 and S7), Guanabenz acetate was se-
lected as the best candidate for enhancing hsiRNA delivery
and efficacy.
alamarBlue R© cellular viability assay
HeLa cell viability following Guanabenz and hsiRNA ad-
ministration was assessed by the alamarBlue R© (Life Tech-
nologies) assay, a fluorescence-based protocol that mea-
sures metabolism in proliferating cells. HeLa cells were
treated with 0–200 M Guanabenz in the presence or ab-
sence of 0.5 M hsiRNA for 24 h in a 96-well plate. Cells
were then incubated for 0–2.5 h with fresh medium contain-
ing 10% alamarBlue. Absorbance at 570 and 600 nm was
measured with a Tecan Infinite M200 microplate reader at
various timepoints. Cellular viability was calculated accord-
ing to the manufacturer’s protocol and normalized to an
untreated control (n = 3, mean ± SD).
Live cell imaging
For live cell uptake monitoring, cells were plated at a den-
sity of 2× 105 cells per 35 mm glass-bottom dish and grown
overnight. Prior to imaging, cell organelles were stained
in HBSS (Gibco) using staining reagents purchased from
Life Technologies unless specified: cell nuclei, endoplas-
mic reticulum and lysosomes were respectively stained us-
ing theNucBlue R© LiveReadyProbe R©, ER-Tracker
TM
Green
(Bodipy FL Glibenclamide) and LysoTracker R© Deep Red
reagents as indicated by themanufacturer. Imaging was per-
formed in non-supplemented DMEM without phenol red
(Invitrogen). Cells were treated with 0.5 Mof Cy3-labeled
hsiRNA, and live cell imaging was performed over time.
Confocal imaging
All confocal images were acquired with a CSU10B Spin-
ning Disk Confocal System scan head (Solamere Technol-
ogy Group) mounted on a TE-200E2 inverted microscope
(Nikon) with a 60x Plan/APO oil lens and a Coolsnap
HQ2 camera (Roper). Images were processed using Im-
ageJ (1.47v) software. Number of neurons without or with
hsiRNA was counted using ImageJ software.
Physicochemical properties of hsiRNA and Guanabenz
Dynamic light scattering measurements were acquired us-
ing a Nano-ZS (Malvern) and analyzed using the DTS
(Nano) program. Two independent measurements, each
with 24 runs, were performed.
Electron micrographs were collected on a transmission
electron microscope (Tecnai Spirit 12, FEI) at the UMMS
Electron Microscopy Core. Samples were prepared by de-
positing 10 l of a hsiRNA and/or Guanabenz solution
onto a carbon-coated copper grid and staining with 2% wt
uranyl acetate.
IC50 calculation
Data analysis was done usingGraphPad Prism 6V6.04 soft-
ware (GraphPad Software, Inc.).
Guanabenz derivative synthesis
All chemicals were purchased from commercial sources and
were used without further purification. Deuterated solvents
were purchased fromSigma-Aldrich. 1HNMRspectrawere
recorded on a Varian 400 MHz NMR spectrometer using
the residual solvent signal as the reference. High-resolution
mass spectra were obtained on a ThermoFinnigan LCQ ion
trap mass spectrometer. Analytical thin-layer chromatogra-
phy (TLC) was performed using silica gel 60 F254 using UV
light as visualizing agent.
Two, four and eight were purchased from commercial
sources. Three and seven were synthesized following previ-
ously reported procedures (20,21). Five and six are not re-
ported in the literature and full synthesis is described in the
Supplemental Methods.
RESULTS
Identification of small molecule enhancers of hsiRNA silenc-
ing in vitro
To directly assess whether co-delivery of small molecules
with hsiRNA could enhance RNAi efficacy, we developed
and validated a high-throughput two-step protocol (Z′ Fac-
tor = 0.74) (Supplementary Figures S1–S3) and performed
a small molecule screen using LOPAC1280 (Library of Phar-
macologically Active Compounds, Sigma–Aldrich) (Fig-
ure 1A). hsiRNA are small, asymmetric, ultra-stable, highly
modified oligonucleotides which efficiently enter cells and
induce silencing without the requirement for formulation
(Figure 1B, modified sequences provided in Supplementary
Table S1) (10). The difference in length between antisense
and sense stands results in a fully phosphorothioated single-
stranded tail, which is believed to work in conjunction with
the sense strand 3′-conjugated cholesterol to promote cel-
lular internalization (personal communication, Dr. Sylvia
Corvera). HeLa cells were co-treated with a panel of 1,280
small molecules and a suboptimal concentration (10 nM)
ofMAP4K4-targeting hsiRNA (Figure 1C, Supplementary
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Figure 1. Screen for small molecules to enhance conjugated therapeutic oligonucleotide efficacy. (A) Small molecule screening strategy. (B) Schematic of the
hydrophobically modified and stabilized siRNAs (hsiRNAs) used in study (see figure legend). (C) Distribution of the classes of bioactive small molecules in
LOPAC library screened during high-throughput assay (Sigma–Aldrich). Workflow of high throughput small molecule screen and hit validation, yielding
Guanabenz (WytensinR©) as a primary hit.
Table S2). A panel of 24 small molecules (1.8% hit rate)
with >50% enhanced protein silencing and minimal toxic-
ity scored as candidate hits (Dual-Glo R©, Promega). These
24 compounds were subjected to a confirmatory assay
(QuantiGene R©, Affymetrix) to measure the impact of small
molecules onmRNA expression levels using aMAP4K4- or
distinct cyclophilin B (PPIB)-targeting hsiRNA sequence
(Supplementary Figure S4), with six candidates confirmed
to have activity (0.5% hit rate), including Phenamil, Caf-
feic acid, Doxepin, BF-170, Furegrelate, and Guanabenz
acetate (Supplementary Figure S5). None of the six candi-
date hits shared apparent structural or functional homol-
ogy, which is not surprising for such a diverse library as
LOPAC. For all subsequent studies, we focused on the com-
pound that induced the most reproducible shift in IC50,
Guanabenz acetate (WytensinTM) (Figure 1C, Supplemen-
tary Figure S6).
Guanabenz (WytensinTM) improves hsiRNA potency and ef-
ficacy in vitro
PPIB mRNA expression levels were monitored after treat-
ment with 10 nM hsiRNA and increasing amounts of
Guanabenz in HeLa cell culture (24 h, Figure 2A). A
concentration-dependent enhancement of hsiRNA activity
is observed, with target mRNA expression dropping from
90% to <10% following treatment with 0–80 M Guan-
abenz (reported as percent of untreated control). Addition-
ally, no effect is seen on mRNA expression following co-
administration of Guanabenz and non-targeting (scram-
bled) hsiRNA (Supplementary Figure S7). Guanabenz-
mediated protein silencing was evaluated using a luciferase
reporter containing a hsiRNA-targeting sequence in the 3′-
UTR (Dual-Glo R©, Promega). In this experiment, treatment
with 0–100 MGuanabenz reduced the hsiRNA IC50 over
100-fold in a dose-dependent fashion from 132 to 2.4 M
(Figure 2B). Under these conditions, Guanabenz itself is
non-toxic and has minimal effect on HeLa cell viability in
the presence or absence of 0.5MhsiRNA (Figure 2C). The
onset ofGuanabenz toxicity occurs at concentrations of 125
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Figure 2. Guanabenz impacts hsiRNA potency and efficacy in a
concentration-dependent manner. (A) Cyclophilin B (PPIB)-targeting
hsiRNA was added to HeLa cells at 10 nM in the presence of increasing
concentrations of Guanabenz. Level of PPIB mRNA was measured us-
ing QuantiGene R© (Affymetrix) at 24 h normalized to housekeeping gene,
MAP4K4 (mitogen-activated protein kinase 4), and presented as percent
of untreated control (n = 3, mean ± SD). UNT – untreated cells, NTC –
non-targeting control, 0.5 M PPIB-targeting hsiRNA served as a posi-
tive control. (B) HeLa cells expressing psiCHECKTM-2 Vector (Promega)
containing PPIB target sequence were incubated with PPIB hsiRNA and
Guanabenz solubilized in DMSO at concentrations shown for 24 h. Level
ofPPIBmRNAwasmeasured using Dual-GloR© Luciferase Assay System
(Promega) normalized to housekeeping gene,MAP4K4, and presented as
percent of 1% DMSO treated cells (ctr) (n = 3, mean ± SD). IC50 values
calculated usingGraphPad Prism 6.04. (C) Cellular viability wasmeasured
by alamarBlue R© (Life Technologies) following incubation of HeLa cells
with 0–200 MGuanabenz in the presence or absence of 0.5 MhsiRNA.
Data presented as percent of untreated control (n = 3, mean ± SD).
M and above for HeLa cells, while U87 and HepG2 cell
lines are more sensitive (Supplementary Figure S8). These
data suggest that Guanabenz is likely to work upstream
of RISC-mediated silencing, as an improvement in efficacy
was observed on both theRNAand protein level. This effect
has been demonstrated with several hsiRNA compounds,
targeting MAP4K4, PPIB, and HTT (Supplementary Fig-
ures S6, S10, S13). The use of direct mRNA quantification
to assess hsiRNA activity against distinct targets ensured
filtering against hits that were sequence, target or assay de-
pendent.
Guanabenz enhances cellular uptake of hsiRNA
We performed live cell imaging of Cy3-labeled hsiRNA
using confocal microscopy to determine whether Guan-
abenz affected the rate or degree of passive hsiRNA cel-
lular uptake. HeLa cells were treated with 0.5 M Cy3-
labeled hsiRNA in the presence or absence of 50MGuan-
abenz (Figure 3). Images were captured every 2min over the
course of 32min at fixed laser intensity and acquisition time.
Over this period, hsiRNA alone is capable of self-delivery
and accumulates on plasma membranes (Figure 3A, left
panel). However, Guanabenz markedly impacts the ability
of hsiRNA to associate with the cell (Figure 3A, right panel,
Supplementary Figure S9). Stable plasma membrane asso-
ciation could be a result of hsiRNA charge shielding via
a non-covalent RNA-Guanabenz interaction. Indeed, the
highly basic guanidinium moiety is analogous to an argi-
nine side-chain, a feature commonly observed in cationic
cell-penetrating peptides such as the HIV-derived TAT pep-
tide or the non-viral penetratin (16,22). The observed im-
pact on the level of hsiRNA cellular association is specific
to early time points, as overall level of internalized oligonu-
cleotides equilibrates by 24 h with no significant alteration
in co-localization with lysosomal markers (Figure 3B). It
appears that the major visible impact of Guanabenz is im-
mediate enhancement of hsiRNA cellular association and
internalization. To investigate if short-term Guanabenz ex-
posure is sufficient to enhance hsiRNA activity, HeLa cells
were treated with range of Guanabenz concentration for 1
h, with hsiRNA IC50 values collected at 24 h (Supplemen-
tary Figure S10). We did not observe any enhancement of
PPIBmRNA silencing, suggesting that the perceived activ-
ity of Guanabenz entails continuous exposure. This might
be due to a requirement for direct small molecule-RNA in-
teractions and/or constitutive modulation of certain intra-
cellular pathways.
We acquired dynamic light scattering (DLS) measure-
ments and transmission electron microscopy (TEM) im-
ages to further investigate the physicochemical properties
of hsiRNA and Guanabenz in solution (Figure 4A). By
DLS, we attempted to detect particles following incuba-
tion of hsiRNAwith varying concentrations of Guanabenz.
No reliable measurements could be collected for 0.5 M
hsiRNA in the presence of 0–200 M Guanabenz, or for
750 M Guanabenz alone. However, we detected polydis-
perse aggregates following incubation of 0.5 M hsiRNA
with 500 or 750 MGuanabenz. For 500 MGuanabenz,
the main species in solution had a calculated hydrodynamic
radius (Z-average) of 63 nm. For 750 M, the major parti-
cle had a hydrodynamic radius of 124 nm. These particles
were highly disperse, with polydispersity indices (PdI) of
0.54 and 0.45, respectively.We confirmed these observations
by TEM, where we observe crystalline hsiRNA particles of
∼100 nm in diameter in the presence of 500 or 750 M
Guanabenz. Furthermore, Cy3-labeled hsiRNA nanoparti-
cles could be detected as a fluorescent pellet following ultra-
centrifugation in the presence of 1 mM Guanabenz (Sup-
plementary Figure S11). Mechanistically, a putative RNA-
Guanabenz interaction may be mediated by the protonat-
able guanidinium moiety, as stable nucleotide-guanidinium
complexes have been described previously (23). We directly
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Figure 3. Guanabenz markedly impacts the rate and degree of intracellular uptake of hsiRNAs. (A) Uptake kinetics of hsiRNA. Cy3-PPIB hsiRNA (red),
0.5 M, was added to HeLa cells in the presence of 1% DMSO or Guanabenz (50 M). Imaged on a Leica confocal microscope, 63X, nuclei stained
with Hoechst dye (blue). Laser intensity and acquisition time were fixed at the 2 min timepoint and kept constant throughout the experiment, resulting in
saturation at later Guanabenz treatment timepoints. (B) Co-localization of hsiRNA with lysosomal markers. Cy3-HTT hsiRNA (red), 0.5 M, was added
in HeLa cells in presence of 1% DMSO or Guanabenz (50 M). Nuclei stained with Hoechst dye (blue) and lysosomes stained with LysoTracker (green,
Life Technologies). Cells were imaged on a Leica confocal microscope, with laser intensity and acquisition optimized for a 24 h experiment. Representative
images taken at time points indicated are shown.
observed weak Guanabenz-hsiRNA binding in vitro by
isothermal calorimetry (ITC) (data not shown) and gel shift
assay (Supplementary Figure S12), in which a large excess
of Guanabenz is required for full complexation of siRNA.
This is substantiated by the fact that over 100-fold mo-
lar excess of Guanabenz is required for enhanced siRNA
biological activity in vitro. The discovery that Guanabenz
could act as a small-molecule siRNA binder agrees well
with reports from Selwood et. al. of guanidinium-based
small molecule-carriers of siRNA, which are based on the
alpha-helical structure of penetratin (16,17). In these stud-
ies, a weak non-covalent RNA-small molecule interaction
is also observed. Taken together, these data imply that a
direct, molecular-scale Guanabenz-hsiRNA interaction oc-
curs and that Guanabenz-hsiRNA nanoaggregates form
at high (non-pharmacologically relevant) concentrations of
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Figure 4. Physicochemical and biological properties of hsiRNA, Guanabenz, and Guanabenz derivatives (A) Characterization of nanoaggregates formed
by hsiRNA and Guanabenz. (Top) Size distribution and intensity measured by dynamic light scattering (Nano-ZS, Malvern). N.D. = not detectable; PdI
= polydispersity index. (Bottom right) hsiRNA nanoparticle size and morphology examined by transmission electron microscopy following incubation
with 500 or 750 MGuanabenz (Tecnai Spirit 12, FEI, 43,000X). Scale bar = 0.2 M. (B) Chemical derivatives and/or functional analogs of Guanabenz
(1) (C) IC50 values of PPIB-targeting hsiRNA following treatment with Guanabenz and derivatives [100 M (1–4, 7,8) or 12.5 M (5,6)] or 1% DMSO.
Derivitization results in loss of effect of Guanabenz on hsiRNA IC50.
Guanabenz. We cannot rule out the possibility for smaller
aggregates to form under our cell treatment conditions, but
they likely represent a small percentage of the total sample
and are undetectable by the methods used herein.
Guanabenz structure-activity relationship analysis
Based on this knowledge, a preliminary SAR analysis was
performed to determine the basic chemical scaffold of Gua-
nabenz required for improving hsiRNA efficacy (Figure 4B,
Compound 1). Specifically, we were interested in determin-
ing whether structural perturbations at any positions were
well tolerated and held potential for being modified into a
linker for the covalent siRNA attachment. A panel of seven
Guanabenz derivatives was prepared and their SAR activ-
ity was explored. We focused on making modifications on
the benzene ring (Figure 4B, Compounds 2–6) and guani-
dinium group (Figure 4B, Compounds 7–8). Compounds 2,
3, 4, 7, and 8were synthesized as described previously. Com-
pounds 5 and 6 were prepared by the procedure described
in the Supplemental Methods. To our surprise, none of the
chemical derivatives showed dose-dependent enhancement
of hsiRNA activity (Supplementary Figure S13). Elimina-
tion of chlorine, modification of the benzene ring, or loss
of guanidinium group all resulted in near complete loss-of-
function. Compounds 5 and 6 were also significantly more
toxic. Calculated IC50 values for the derivatives are listed in
Figure 4C.
This finding is supported by an in-depth structural anal-
ysis of the small molecule screening data, which revealed
∼30 compounds containing protonatable primary amines
or guanidinium groups that were not identified as posi-
tive hits (Supplementary Table S3). This implies a mecha-
nism more complex than a purely electrostatic-based inter-
action, in which a protonated Guanabenz masks the neg-
ative charge of siRNA and facilitates uptake. Collectively,
this suggests that Guanabenz may be enhancing hsiRNA
uptake through weak, non-covalent interactions, but also
mediating enhanced gene silencing through independent
modulation of cellular pathways.
Mechanistic analysis of observed guanabenz activity
Guanabenz acetate was FDA approved in 1982 as an al-
pha agonist of -adrenoreceptor for the treatment of hy-
pertension (24). Recently, it has been implicated as an in-
hibitor of several fundamental cellular pathways, includ-
ing the protein-folding activity of the ribosome (PFAR)
(25) and protein dephosphorylation by protein phosphatase
1 (PP1) (26–28). Both of these functionalities have been
linked to neuroprotective anti-prion activity (29,30). To
date, there has been no link between cellular pathways af-
fected by Guanabenz and RNA trafficking, endocytosis,
or therapeutic siRNA-dependent mRNA silencing. To ver-
ify that Guanabenz may act through a trans mechanism
independent of RNA binding, we tested a panel of small
molecule compounds that have alpha-2 adrenergic ago-
nist or PP1-inhibitory activity. Clonidine is another FDA-
approved therapeutic for hypertension and a chemical ana-
log of Guanabenz (29). A dose response of a Huntingtin
(HTT)-targeting hsiRNA was performed in the presence
of 100 M Clonidine or 60 M Guanabenz (Supplemen-
tary Figure S14, structure Figure 4B). In this assay, Guan-
abenz enhanced HTT mRNA silencing by ∼30% over an
untreated (1% DMSO) control. However, treatment with
100 M Clonidine had no effect. A similar assay was done
using Salubrinal, a specific inhibitor of GADD34, which is
a non-enzymatic cofactor of PP1 (30). A dose response of
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HTT-targeting hsiRNA was performed in the presence of
25, 50, or 75 M Salubrinal (Supplementary Figure S14,
structure Figure 4B). Under these conditions, Salubrinal
had no effect on hsiRNA efficacy. These data imply that
the activity of Guanabenz towards hsiRNA is not related to
alpha-2 adrenergic agonist or protein phosphatase-related
functionality. Taken together, these data suggest that Gua-
nabenz may be enhancing hsiRNA uptake and activity in a
trans mechanism that has not been previously described.
Finally, we examined the impact of Guanabenz co-
delivery on mRNA silencing efficacy of GalNAc-siRNA,
LNA antisense, and sterol-conjugated siRNA (Accell
siRNA, Thermo Fisher) in primary human hepatocytes
(Supplementary Figure S15). We report that Guanabenz
shows no activation of other classes of ONTs. This exem-
plifies the fact that small molecules can demonstrate speci-
ficity towards certain uptake and intracellular trafficking
pathways, and points to the need for separate screening pro-
tocols for each class of compound. The only reported in-
stance of smallmolecule-mediatedONTactivation isRetro-
1. Retro-1 was identified in a screen for compounds which
block retrograde trafficking, and was shown to increase the
activity of antisense and splice-switching oligonucleotides,
but not siRNA (18). We evaluated the impact of Retro-1
on hsiRNA efficacy and observed that co-treatment with
100 MRetro-1 had a slightly inhibitory effect, confirming
that hsiRNA transport is not mediated through a Retro-1
dependent pathway (Supplementary Figure S14, structure
Figure 4A). Taken together, these data indicate that com-
pounds that are both cholesterol- and phosphorothioate-
modified are internalized through a pathway selectively en-
hanced by Guanabenz.
DISCUSSION
In summary, in a proof-of-concept search for small
molecule modulators of siRNA activity, we identified
Guanabenz acetate (WytensinTM) from a high-throughput
screen of 1280 pharmacologically active small molecules.
We established that co-delivery of Guanabenz acetate with
hsiRNA allows a 100-fold improvement in hsiRNA IC50,
due in large part to a dramatic increase in hsiRNA cellu-
lar membrane association and internalization. This func-
tionality is sequence independent, but ONT class specific.
The identification of small molecules with a profound im-
pact on hsiRNA efficacy was surprisingly straightforward,
with several hits isolated from a highly diverse but relatively
small sized library. A similar combinatorial approach pre-
viously revolutionized the field of lipidoid-mediated siRNA
delivery, identifying novel chemical scaffolds with un-
precedented efficacy (31,32). For gymnotic oligonucleotides
(ASO, GalNAc-siRNAs, hsiRNA) our work illustrates the
potential for small molecule screening to become the foun-
dation for rational design of novel classes of conjugated
ONTs or combinatorial small molecule-ONT formulations.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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